The Grail Galleri test is a multi-cancer early detection (MCED) blood test that looks for DNA fragments shed by tumors across more than 50 cancer types, many of which have no routine screening test. In the 2026 PATHFINDER 2 (n = 32,007) and NHS-Galleri (n = 142,250) trials, Galleri showed 99.5 to 99.6% specificity, a 46 to 60% positive predictive value, and 91 to 93% accuracy in naming the organ of origin, while lowering Stage IV diagnoses by 14% overall (26% by Round 3) and cutting emergency cancer diagnoses by 21.3%. However, it misses 83% of Stage I cancers (16.8% Stage I sensitivity) and did not lower combined Stage III and IV diagnoses in NHS-Galleri (IRR 1.03) because many tumors were caught at Stage III instead of Stage I. At Fishtown Medicine, we treat Galleri as an additive layer: we optimize your immune and metabolic foundations and complete all regular screenings first, stay attentive to small symptoms, and consider Galleri every 1 to 2 years for proactive adults 50+ or those with cancer in their family story.
TL;DR: The Grail Galleri blood test checks a single blood draw for tumor DNA across dozens of cancers, including ovarian, pancreatic, liver, esophageal, and blood cancers that have no routine screening test.
- What we hoped for vs. what the 2026 trials showed: We wanted to see strong Stage I and II detection. Instead, Galleri is very effective at catching Stage III and IV cancers (77 to 90%), while missing most tiny Stage I cancers (16.8% overall; 37% across 12 aggressive types).1,2 In the 142,250-person NHS-Galleri trial, Stage IV cancers dropped 14% (26% by year three) and emergency diagnoses fell 21.3%, while Stage III diagnoses rose to offset them (IRR 1.03).1
- What a positive or negative result means (PATHFINDER 2, 2026): Specificity is 99.64%. When a signal fires, 6 in 10 are confirmed cancer (60.3% PPV) and 4 in 10 are false alarms that take a median of 70 days of targeted scans to rule out.3 A negative result still misses 60 to 70% of cancers appearing over the next year, so it never clears a new symptom.3,4
- How we sequence it: First, we strengthen your immune and metabolic terrain (Vitamin D to 70 ng/mL, ferritin, fasting insulin, sleep) and complete all regular organ screenings. Then, for proactive adults 50+ or patients with cancer in their family story, we consider layering Galleri once a year (higher risk) or every 2 years (moderate risk) as an additive check.5
On a phone call last week, a patient whose mother and aunt had both faced cancer asked me whether spending $949 on the Galleri blood test meant she could breathe easy for the year. I shared what I tell every family in my practice: the big 2026 trial showed Galleri is not as strong at catching tiny Stage I and II tumors as we all hoped, while being very effective at catching Stage III and IV cancers that have no routine screening test. That means a normal blood draw never replaces building your immune terrain, staying on top of mammograms and colonoscopies, or checking a small new symptom right away.
Why does proactive cancer prevention start with your immune terrain and regular screenings?
Every human being makes mutated cells inside their body every day. A strong immune system spots and clears those mutated cells before they can grow into a tumor. When a mutated cell slips past immune checks and hides as normal tissue, it can keep dividing.
Before we talk about a pricey, non-FDA-approved blood test like Galleri (~$949 self-pay), we handle the foundations that shape your daily biology:
- Immune and metabolic terrain: High fasting insulin and belly fat feed dividing cells, while poor sleep, low Vitamin D (we target 70 ng/mL), and low iron reserves (ferritin) weaken immune defense.
- Regular organ screenings: Colonoscopy, mammography (or breast MRI / ultrasound), cervical HPV/Pap testing, PSA + multiparametric MRI, skin exams, and low-dose chest CT (for eligible smokers) either remove precancerous growths or catch tiny Stage I tumors before they shed DNA into your blood.
Figure: Across CCGA3, PATHFINDER 2 (n = 32,007), and the 142,250-adult NHS-Galleri trial, Galleri caught 77 to 90% of Stage III-IV cancers and cut Stage IV diagnoses by 14 to 26%, while missing 83% of Stage I tumors. In primary care, we optimize immune/metabolic foundations and routine organ screenings first before layering Galleri every 1 to 2 years.
What does the Galleri blood test do well, and where does it fall short?
Galleri is strong at flagging fast-growing, unscreened cancers once they shed DNA into the blood, and weak at catching small Stage I tumors that stay behind tissue barriers.1,2,3
About 70% of cancer deaths in the United States come from tumors that have no routine screening test at all. Those include ovarian, pancreatic, liver, bile duct, esophageal, stomach, head and neck, lymphoma, and myeloma. When Galleri flags a signal, its Cancer Signal Origin (CSO) prediction names the right organ 91 to 93% of the time.3,4 That lets us aim an MRI, CT, or scope straight at that organ. In the first PATHFINDER study, 74% of the cancers Galleri caught were types with no standard screening test.6
The trade-off is stage sensitivity. In the CCGA3 validation study (n = 4,077), detection rose sharply with tumor stage:2
- Stage I: 16.8% across all cancers (37% across the 12 deadliest cancer types).
- Stage II: 40.4% across all cancers (70% across the 12 deadliest types).
- Stage III: 77.0% across all cancers (87% across the 12 deadliest types).
- Stage IV: 90.1% across all cancers (93% across the 12 deadliest types).
In plain terms, the big trials showed that Galleri is not yet the Stage I and II detector we all wished for. It acts mainly as a Stage II, III, and IV net for cancers that have no other test.
What did the 2026 NHS-Galleri and PATHFINDER 2 trials prove?
In late 2026, two large trials gave us clear numbers on how Galleri performs in healthy adults over 50:1,3,4
| Study & Design | What It Found When Positive (Specificity, PPV, CSO) | What It Caught vs. Missed (Sensitivity & Stage Shift) | Workup Timeline & Practical Meaning |
|---|---|---|---|
| PATHFINDER 2 (Nature Medicine Sept 2026, n = 32,007 adults >= 50) | Specificity 99.64%; PPV 60.3% (up from 38 to 43% in PATHFINDER 1); CSO accuracy 91.3%. | Caught 39.3% of all cancers appearing within 1 year (69.8% of the 12 lethal types); 53% of new cancers found were Stage I or II. | Median 37 days to confirm cancer vs. 70 days to clear a false alarm (down from 162 days in PATHFINDER 1). Only 0.6% of all tested adults needed a biopsy or scope. |
| NHS-Galleri RCT (NEJM & Nature Medicine Oct 2026, n = 142,250, 3 annual draws) | Specificity 99.5 to 99.6%; PPV 58.0% (Rd 1) -> 50.4% (Rd 2) -> 45.8% (Rd 3); CSO 91.1 to 93.6%. | Primary Stage III + IV endpoint missed (IRR 1.03): fewer Stage IV cases (341 vs. 394, -14% overall, -26% in Round 3) were offset by more Stage III cases (360 vs. 287). | Emergency hospital cancer diagnoses dropped 21.3%, while 12-month sensitivity ran 37.2% in Round 1 and ~27% in Rounds 2 and 3. Five-year survival data are still pending. |
| SYMPLIFY (Lancet Oncology 2023, n = 5,461 symptomatic referrals) | Specificity 98.4%; PPV 75.5% (high because 6.7% of symptomatic patients already had cancer). | Sensitivity 66.3% overall (Stage I still 24.2%). | Tested people who already had red-flag symptoms; a negative test (2.4% false-negative rate) cannot be used to skip a symptom workup.7 |
Why is Galleri strictly additive to regular screening and symptom checks?
Fishtown Medicine
A 90-minute conversation with Dr. Ash. A written plan you can follow.
A "No Cancer Signal Detected" report barely changes your chance of having an early, slow-shedding cancer (negative likelihood ratio 0.61 in PATHFINDER 2). It can never replace your regular screenings or quiet a new symptom.3,5
In PATHFINDER 2, 61% of the cancers Galleri missed were breast, prostate, colon, lung, or cervical cancers that already have standard screening tests.3 Specifically, Galleri misses:
- 97.4% of Stage I breast cancers (2.6% sensitivity) - mammography, breast MRI, and breast ultrasound catch these while they are still localized.2
- 97.5% of melanomas (4 of 157 caught in NHS-Galleri) - a dermatologist's visual skin check catches these on the surface.4
- About 90% of localized prostate cancers (9 to 11% sensitivity) - PSA density and multiparametric MRI catch these early.2,4
- Precancerous colon polyps and cervical precancer (CIN) - colonoscopy and HPV/Pap testing prevent cancer by removing precancerous tissue before it turns malignant.
Just as important, it is 2026 and we still do not have a blood test that rules out early cancer when you feel something off. If you notice new bruising, a lump, a change in bowel habits, postmenopausal bleeding, or lasting pain, we check that symptom right away even if your Galleri test was normal last month.
How Fishtown Medicine Approaches Galleri (1-Year vs. 2-Year Cadence)
Instead of treating Galleri as either a miracle test or a useless one, we place it in a calm, four-part order:
- Optimize the terrain and finish regular screenings first: We dial in your Vitamin D (70 ng/mL), ferritin, fasting insulin, ApoB, and sleep. We also make sure your colonoscopy, breast imaging, cervical screen, prostate check, and skin exam are current.
- Match the cadence to your personal and family story: Once your foundations are set, if cancer runs in your story (for example, a parent or sibling with ovarian, breast, pancreatic, stomach, or blood cancer, even when BRCA or Lynch testing is negative) or you want an additive net for unscreened organs after age 50, we can put Galleri in your plan:
- Higher-risk family or exposure stories: We consider it once a year.
- Moderate-risk proactive adults (50+): We often space it to every 2 years.
- Quarterback any positive signal calmly: If a signal ever comes back positive, you are not left alone with a scary PDF. We use the 91%-accurate organ prediction to order the targeted MRI, CT, or scope needed and walk with you until it is resolved.
Key Takeaways
- Galleri supplements routine screening without replacing it: Keep colonoscopy, mammography, low-dose chest CT for eligible smokers, and cervical screening current because blood-based MCED testing is strictly an additive second layer.
- High specificity pairs with low Stage I sensitivity: Galleri carries roughly 99.5% specificity (0.4% to 0.5% false-alarm rate) and accurately points to tissue of origin, yet catches only 16.8% of Stage I cancers because tiny tumors shed minimal DNA.
- Clinical trials clarify predictive value and stage-shift limits: NHS-Galleri and PATHFINDER 2 data show positive predictive values near 43% to 62%, while long-term endpoints weigh whether earlier detection lowers overall cancer deaths.
- CADENCE matches testing cadence to personal risk: Low-risk adults under 50 skip MCED testing, whereas elevated-risk adults 50+ weigh annual or biennial draws with clear counseling on false-negative limits.
Related at Fishtown Medicine
- What the NHS-Galleri Trial Showed - deeper dive into the 142,250-person NEJM randomized trial
- Advanced Cancer Screening - how we layer immune foundations, regular screening, genetics, Galleri, and MRI-DWI
- Preventing Heart Disease and Cancer Blueprint - our complete Tier 1 and Tier 2 prevention architecture
- Full-Body MRI: What the Data Show - how radiation-free MRI-DWI compares with liquid biopsy
- Your PSA Came Back High - the multiparametric MRI and PSA density pathway before prostate biopsy
Scientific References
- Sasieni P, Johnson P, Round T, et al. "Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis (NHS-Galleri)." The New England Journal of Medicine. 2026 Oct 8.
- Klein EA, Richards D, Cohn A, et al. "Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set (CCGA3)." Annals of Oncology. 2021;32(9):1167-1177.
- Nabavizadeh N, McDonnell C, Kurbegov D, et al. "Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study." Nature Medicine. 2026 Sep 22.
- Neal RD, Dolly S, Johnson P, et al. "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial." Nature Medicine. 2026.
- Hoffman RM, Wolf AMD, Raoof S, et al. "Multicancer Early Detection Testing: Guidance for Primary Care Discussions With Patients." Cancer. 2025.
- Schrag D, Beer TM, McDonnell CH, et al. "Blood-Based Tests for Multicancer Early Detection (PATHFINDER): A Prospective Cohort Study." The Lancet. 2023;402(10409):1251-1260.
- Nicholson BD, Oke J, Virdee PS, et al. "Multi-Cancer Early Detection Test in Symptomatic Patients Referred for Cancer Investigation in England and Wales (SYMPLIFY)." The Lancet Oncology. 2023;24(7):733-743.
- Hunter DJ. "A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer." The New England Journal of Medicine. 2026 Oct 8.
Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. He practices proactive, evidence-based primary care that combines metabolic and immune optimization with thoughtful cancer screening.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





